Phase 3
Completed N=25
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Glabellar Frown Lines · Canthal Lines
Source: ClinicalTrials.gov NCT05148000 ↗
Enrolled (actual)
25
Serious AEs
0.0%
Results posted
May 2026
Primary outcomePrimary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study to assess aesthetic improvement following treatment with QM1114-DP.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) |
100 | — |
| PRIMARY Responders Rate Using the GAIS at Maximum Smile (Lateral Canthal Lines) |
100 | — |
Eligibility Criteria
Inclusion Criteria
- Male or Female 18 years or older
- Moderate to severe bilaterally symmetrical LCL as assessed by the investigator
- Moderate to severe GL at maximum frown as assessed by the Investigator
Exclusion Criteria
- Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment
- Female who was pregnant, breast feeding or intended to conceive a child during the study.
- Known allergy to hypersensitivity or any component of the Investigational product
Data sourced from ClinicalTrials.gov (NCT05148000). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.